Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

Glutathione S-Transferase È¿¼ÒÀ¯ÀüÀÚ ´ÙÇü¼º°ú ÀڱðæºÎ¾ÏÀÇ À¯ÀüÀû °¨¼ö¼º Glutathione S-Transferase Polymorphisms and Genetic Susceptibility to Cervical Cancer

´ëÇѾÏÇÐȸÁö 1997³â 29±Ç 4È£ p.673 ~ 680
¼Ò¼Ó »ó¼¼Á¤º¸
±èÁø¿ì ÀÌÃá±Ù/¼Õ¿©¿ø/¹ÎÈ«±â/ÇѼö¹Ì/Á¶Àº¿µ/±è°æ¼÷/½ÅÁø¿õ/±è»çÁø

Abstract

¼­·Ð
ÀڱðæºÎ¾ÏÀº ±× ¹ß»ýÃß¼¼°¡ º¯È­Çϱ⠽ÃÀÛÇÏ¿© 1980³â ÈĹÝÀÌÈÄ 30´ë Áß¹ÝÀÇ ÀþÀº ¿©¼º
µé¿¡¼­ ÈçÈ÷ ¹ß°ßµÇ°í ÀÖÀ¸¸ç ±× Á¶Á÷ÇÐÀû ºÐÈ­µµµµ ´õ ¾Ç¼ºÀ̸ç ÀÓÆÄÀý ÀüÀÌ¼Ò°ß µîµµ Èç
ÇÏ°Ô º¸°íµÇ°í ÀÖ¾î °á±¹ ÀþÀº ¿©¼ºµé¿¡¼­ ¹ß»ýÇÏ´Â ÀڱðæºÎ¾ÏÀÇ °æ¿ì ±× »ýÁ¸À²Àº ¾ÆÁÖ
³·°Ô º¸°íµÇ°í ÀÖ´Ù.
ÇöÀç ÀڱðæºÎ¾ÏÀÇ ¹ß»ý¿øÀÎÀÇ Áß¿äÇÑ ¿øÀÎÀÎÀڷδ Àΰ£ À¯µÎÁ¾ ¹ÙÀÌ·¯½º(human
papillomavirus, ÀÌÇÏ HPV·Î ¾àÇÔ)°¡ °¡Àå Å« ¿ªÇÒÀ» ÇÏ´Â °ÍÀ¸·Î º¸°íµÇ°í ÀÖÀ¸³ª, Á¤»ó
¿©¼º¿¡¼­µµ ¹ß¾Ï¼º HPV µéÀÌ °ËÃâµÇ°í ÀÖÀ¸¸ç ÀÌÁß¿¡¼­µµ ¼Ò¼ö¿¡¼­¸¸ÀÌ ÀڱðæºÎ¾ÏÀ¸·Î
ÀÌÇàµÇ°í ÀÖ´Ù. µû¶ó¼­ HPV °¨¿°À¸·Î¸¸ ÀڱðæºÎ »óÇÇÁ¶Á÷ÀÇ ¾Ç¼ºº¯È­°¡ Ç×»ó µ¿¹ÝµÇ´Â °Í
Àº ¾Æ´Ï°í ÀÌ¿Ü¿¡µµ ÀڱðæºÎ¾Ï ¹ß»ý¿¡´Â ȯ°æÀÎÀÚ, ¸é¿ªÇÐÀû Ư¼º ¹× À¯ÀüÀû ÀÎÀÚµéÀÌ ÇÔ
²² º¹ÇÕÀûÀ¸·Î ÀÛ¿ëÇÏ°í ÀÖ´Â °ÍÀ¸·Î ÃßÁ¤µÇ°í ÀÖ´Ù. ÀÎü°¡ ¿©·¯ °¡Áö È­ÇÐÀû ¹ß¾Ï¿ø¿¡ ³ë
ÃâµÇ¾úÀ» ¶§ ½ÇÁ¦ ƯÁ¤ ¾ÏÀ» ÀÏÀ¸Å°´Âµ¥´Â ¹ß¾Ï¿ø ÀÚü°¡ °¡Áø ¼ºÁúÀ̳ª, ³ëÃâÁ¤µµ µîµµ Áß
¿äÇÑ ÀÎÀÚÀÌÁö¸¸, °¢ °³ÀÎÀÌ °¡Áø À¯ÀüÀû °¨¼ö¼ºÀÇ Â÷ÀÌ¿¡ ÀÇÇؼ­µµ Å©°Ô ¿µÇâÀ» ¹Þ´Â´Ù.
ÀڱðæºÎ¾ÏÀÇ °æ¿ìµµ Èí¿¬°ú ÀûÁö ¾ÊÀº »ó°ü°ü°è°¡ ÀÖÀ¸¸ç, Èí¿¬ÀÚ Áý´Ü¿¡¼­ ÀÎÀ¯µÎÁ¾¹Ù
ÀÌ·¯½ºÀÇ °¨¿°ºóµµ°¡ ³ô°í ¶ÇÇÑ ÀڱðæºÎ¾ÏÀÇ ¹ß»ýºóµµµµ ³ôÀº °ÍÀ¸·Î º¸°í µÇ°íÀÖ´Ù. ÃÖ±Ù
Èí¿¬°ú ¹ÐÁ¢ÇÑ °ü°è¸¦ °®°í ÀÖ´Â °¢Á¾ ¾ÏµéÀÇ ¹ß»ý¿¡¼­ ÀÌ·¯ÇÑ °³Àΰ£ À¯ÀüÀû ¼ö¼º Â÷ÀÌ¿¡
´ëÇÑ ¿¬±¸°¡ È°¹ßÈ÷ ÁøÇàµÇ°í ÀÖ´Ù.
ÀÌ·¯ÇÑ À¯ÀüÀû °¨¼ö¼ºÀ» °áÁ¤Áþ´Â ´ëÇ¥ÀûÀÎ ÀÎÀÚµé·Î´Â cytochrome P450(CYP1Al,
CYP2E1, CYP2D6)°ú glutathione S-transferase(GST M1, GSTT1)µé°ú °°Àº ¾à¹°´ë»çÈ¿¼Ò
°¡ °ü·ÃµÇ¾î ÀÖÀ¸¸ç, À̵é È¿¼ÒÀÇ À¯ÀüÀÚ ´ÙÇü¼º¿¡ ±âÀÎµÇ¾î ³ªÅ¸³ª´Â ¹ßÇöÁ¤µµÀÇ Â÷ÀÌ¿¡
µû¶ó °³Àΰ£ ¾Ï¹ß»ýÀÇ À¯ÀüÀû °¨¼ö¼º¿¡ Â÷ÀÌ°¡ ³ªÅ¸³ª´Â °ÍÀ¸·Î ¹àÇôÁö°í ÀÖ´Ù. À̵é È¿¼Ò
Áß GST È¿¼Ò´Â phase II ´ë»çÈ¿¼Ò·Î¼­ ¿©·¯ °¡Áö È°¼ºÈ­µÈ ¾ÏÀü±¸¹°Áú(procarcinogen)µéÀÇ
ȯ¿øÇü glutathione Æ÷ÇÕ¹ÝÀÀÀ» Ã˸ÅÇØ ÁÜÀ¸·Î½á Çص¶ÇØÁÖ´Â ±â´ÉÀ» °¡Áö°í ÀÖÀ¸¸ç, ¾Æ¹Ì³ë
»ê±¸¼º¹è¿­ÀÇ Â÷ÀÌ¿¡ µû¶ó Mu, alpha, Pi, theta classµé·Î ±¸ºÐµÇ¸ç, ÀÌÁß Mu classÀÇ
GSTM1, theta classÀÇ GSTT1 ´ÙÇü¼ºÀÌ À¯ÀüÀû °¨¼ö¼º °áÁ¤¿¡ Å©°Ô ÀÛ¿ëÇÏ´Â °ÍÀ¸·Î º¸°í
µÇ°í ÀÖ´Ù.
GST È¿¼Ò´Â benzo(¥á)pyreneÀÇ È°¼ºÈ­µÈ ´ë»ç¹°ÁúÀ» Çص¶½ÃÅ°´Âµ¥ Áß¿äÇÑ ¿ªÇÒÀ» ÇÏ°í
ÀÖÀ¸¸ç, ÀÌ È¿¼ÒÀÇ °áÇÌÇüÀÌ Èí¿¬°ú °ü·ÃµÈ °¢Á¾ ¾Ï¿¡ °É¸± À§Ç輺ÀÌ Å« °ÍÀ¸·Î ¾Ë·ÁÁ® ÀÖ
´Ù.
±×·¯³ª, À¯ÀüÀÚ ´ÙÇü¼ºÀº ÀÎÁ¾¿¡ µû¸¥ À¯ÀüÀÚ ±¸¼ºÀÇ Â÷ÀÌ·Î ÀÎÇØ ±× À¯ÀüÀÎÀÚ ºóµµ¿Í ºÐ
Æ÷ µî¿¡¼­ Â÷ÀÌ°¡ ÀûÁö ¾Ê°Ô Á¸ÀçÇÏ°í À־, ƯÁ¤ ÀÎÁ¾ÀÇ Èí¿¬°ü·Ã ¾Ï¿¡¼­µµ À¯»çÇÑ °á°ú
¸¸À» º¸ÀÌÁö´Â ¾ÊÀ» °ÍÀÌ´Ù. ÇöÀç±îÁö Æó¾Ï¿¡ ´ëÇÏ¿©¼­´Â CYP450°ú GST À¯ÀüÀÚµé ºÐ¼®Àº
ºñ±³Àû ¸¹ÀÌ ÀÌ·ç¾îÁ® ¿ÔÀ¸³ª, ÀڱðæºÎ¾Ï°ú °ü·ÃµÈ º¸°í´Â Àü¼¼°èÀûÀ¸·Î ¹Ì¹ÌÇÑ ½ÇÁ¤À̸ç,
±× ºÐ¼® ´ë»óÀÌ ¼­¾çÀΰú ÀϺ»Àΰú °°Àº ¸î ÀÎÁ¾¿¡ ´ëÇؼ­¸¸ Á¦ÇÑÀûÀ¸·Î ÁøÇàµÇ¾î ¿ÔÀ» »Ó
Çѱ¹Àο¡ ´ëÇؼ­´Â ÀüÇô ¿¬±¸°¡ µÇ¾î ÀÖÁö ¾Ê´Ù.
º» ¿¬±¸´Â ÀڱðæºÎ¾ÏÀÇ ¹ß»ýÀÌ Èí¿¬À» ºñ·ÔÇÑ ¿©·¯ °¡Áö ȯ°æÀû ÀÎÀÚ Áï È­ÇÐÀû ¹ß¾Ï¿ø
¿¡ ÀÇÇØ ¿µÇâÀ» Å©°Ô ¹Þ°í ÀÖ´Ù´Â Á¡¿¡ Âø¾ÈÇÏ¿© Çѱ¹ÀÎÀÇ ÀڱðæºÎ¾ÏȯÀÚ Áý´Ü¿¡¼­ È­ÇÐÀû
¹ß¾Ï¿øÀ» ´ë»ç½ÃÅ°´Â GST È¿¼ÒÀÇ À¯ÀüÀû ´ÙÇü¼ºÀÌ ½ÇÁ¦ ÀڱðæºÎ¾ÏÀÇ ¹ß»ý¿¡ °ü¿©µÇ°í ÀÖ
´ÂÁö¸¦ ºÐÀÚ À¯ÀüÇÐÀû ¹æ¹ýÀ¸·Î ºÐ¼®ÇÏ¿© ÀڱðæºÎ¾Ï¿¡¼­ÀÇ À¯ÀüÀû °¨¼ö¼ºÀ» °áÁ¤ÇÏ°íÀÚ ½ÃµµµÇ¾ú´Ù.
#ÃÊ·Ï#
Purpose: The identification of genetic traits that predispose individuals to
environmentally induced cancers is one of the challanges in the assessment of individual
cancer risk. The genetically determined differences in metabolism, related to glutathione
S-transferases(GSTs) have been reported to be associated with various cancer
susceptibility. The present study was set up to establish the frequencies of the
polymorphic genotypes of two GST(GST-mu and GST-theta) isozymes in Korea, to
evaluate a possible increased incidence of the genotypes associated with higher cervical
cancer risks among Korean cervical cancer patients.
Materials and Methods: In this study, extracted DNAs from cervical cancer
patients(228 for GST-mu and 241 for GST-theta genotypes) and normal controls(360 for
GST-mu and 353 for GST-theta genotypes) were analysed with the polymerase chain
reaction(PCR).
Results: The overall genotype distribution of the GST-theta polymorphisms was not
statistically different between the patients and control groups. But, in the GST-mu null
genotypes, there were remarkable differences between patients and control groups when
the cervical cancer patients were devided into subgroups with respect to the age. The
frequency of GST-mu null polymorphisms in the cervical cancer patients under the 40
years old was significantly higher compared to the patients above the 40 years
old(0.01were correlated to far advanced clinical stages(stages III and IV)(0.05parameters including histological type and degree of differentiation were not correlated
with GST polymorphism.
Conclusion: These results strongly suggest that individuals carrying GST-mu(null)
alleles are genetically susceptible to cervical cancer which develops before 40 years of
age and GST-mu null genotype may play a some role in cervical cancer progression.

Å°¿öµå

Cervical cancer; Genetic susceptibility; Glutathione S-Transferase;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KoreaMed
KAMS